Investments
154Portfolio Exits
25Funds
8Service Providers
1About Cota Capital
Cota Capital is an SEC-registered multi-stage investment firm focused on private and public enterprise technology companies. Cota has invested in more than 100 private and public technology companies since inception. Cota's overall Mission is to deliver impactful outcomes through principle-guided investment in modern enterprise technologies.
Want to inform investors similar to Cota Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Cota Capital News
Sep 28, 2023
Share This Article • Financing led by M Ventures, with participation from GreatPoint Ventures, Riverine Ventures and existing investors Cota Capital, Dynamk Capital, Elm Street Ventures, Embark Ventures, EGB Capital and Khosla Ventures • Novel microfluidics-based cell engineering platform for ex-vivo cell transfection enabling efficient, flexible, and consistent payload delivery, superior cell health and streamlined workflows for seamless scalability from research to manufacturing • Funding to advance the development of CellFE's technology platform and support the company's market launch and continued growth initiatives ALAMEDA, Calif., September 27, 2023-- CellFE Inc., www.cellfebiotech.com, a life sciences tools company developing a microfluidics-based cell engineering platform dedicated to transforming the development and manufacturing of advanced cell therapies, today announced the completion of a $22 million Series A financing led by M Ventures, with participation from Great Point Ventures and Riverine Ventures as well as existing investors Cota Capital, Dynamk Capital, Elm Street Ventures, Embark Ventures, EGB Capital, and Khosla Ventures. The continued clinical and commercial success of advanced biologic therapeutics, such as engineered cell and gene therapies, is driving substantial growth opportunities in this emerging segment of life sciences. Therapy developers are forging partnerships with technology providers, such as CellFE, to advance innovative solutions, with the aim to benefit patients seeking better therapeutic options. CellFE's innovative, non-viral, microfluidic cell engineering platform, Infinity MTx™ system, performs complex genetic cell editing through streamlined, advanced workflows. The platform ensures gentle cell treatment, rapid cell recovery, and superior yield of healthy cells, enabling unparalleled scalability and significant time and cost efficiencies in development and manufacturing. CellFE empowers therapy developers to accelerate the ongoing evolution of advanced cell therapies across a spectrum of therapeutic areas, unlocking a groundbreaking shift towards true decentralized and point-of-care manufacturing in the cell therapy sector. The launch of the Infinity MTx system at the recent ASGCT 2023 Annual Meeting elicited broad interest from top innovative cell therapy developers globally. "With our clear path to help redefine cell therapy manufacturing, we are excited to have the backing of such esteemed investors who recognize the potential of our technology and the strength of our team," said Alla Zamarayeva, CEO of CellFE. "Our vision of advancing the platform to a decentralized and point of care application will expand access to cell therapies for millions of patients." "While viral cell engineering methods have been dominating the industry to date, high costs, limited editing capabilities, regulatory hurdles, and safety concerns are driving a shift to non-viral methods. CellFE presents a unique technology platform addressing key industry pain points across viral, but also other non-viral methods," said Christian Uhrich, Principal at M Ventures. "Offering efficient, flexible, and consistent payload delivery, superior cell health, user-friendly workflows, and process scalability from development to manufacturing, we believe the company offers a compelling value proposition for the increasing number of therapy developers seeking novel solutions. We are delighted to join the company that Alla and the CellFE team have built at this exciting time and to support the company's future development, growth, and overall vision." About CellFE CellFE is an innovative microfluidics company, whose mission is to transform the development and manufacturing of lifesaving cell therapies to make them more accessible to patients. The company uses a microfluidic-based cell engineering platform with highest cell health and payload delivery, streamlined scalability and automated workflows. Platform benefits include increased cell yield and reduced expansion times that translate to drastically reduced vein-to-vein times and manufacturing costs currently associated with advanced cell therapies. CellFE is committed to enabling their partners' success through close collaborations that aim to solve the challenges associated with the development and manufacturing of next generation cell therapies. https://www.cellfebiotech.com/ About M Ventures M Ventures is the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany. From its headquarters in the Netherlands and offices in Germany, USA and Israel, M Ventures invests globally in transformational ideas driven by innovative entrepreneurs. Taking an active role in its portfolio companies, M Ventures teams up with management teams and co-investors to translate scientific discoveries into commercial success. M Ventures focuses on identifying and financing novel solutions to some of the most difficult challenges, through company creation and equity investments in fields that will impact the vitality and sustainability of Merck KGaA, Darmstadt, Germany's current and future businesses. http://www.m-ventures.com/
Cota Capital Investments
154 Investments
Cota Capital has made 154 investments. Their latest investment was in CellFE as part of their Series A on September 9, 2023.
Cota Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
9/27/2023 | Series A | CellFE | $22M | No | Cota Capital, Dynamk Capital, EGB Capital, Elm Street Ventures, Embark Ventures, GreatPoint Ventures, Khosla Ventures, M Ventures, Riverine Ventures, and Undisclosed Investors | 2 |
9/27/2023 | Series B | Farther | $31M | No | 2 | |
7/27/2023 | Series B | Proprio | $43M | No | Bird B, BOLD Capital Partners, Cota Capital, DCVC, HTC, Intel, and Undisclosed Investors | 4 |
7/11/2023 | Series B | |||||
5/30/2023 | Unattributed |
Date | 9/27/2023 | 9/27/2023 | 7/27/2023 | 7/11/2023 | 5/30/2023 |
|---|---|---|---|---|---|
Round | Series A | Series B | Series B | Series B | Unattributed |
Company | CellFE | Farther | Proprio | ||
Amount | $22M | $31M | $43M | ||
New? | No | No | No | ||
Co-Investors | Cota Capital, Dynamk Capital, EGB Capital, Elm Street Ventures, Embark Ventures, GreatPoint Ventures, Khosla Ventures, M Ventures, Riverine Ventures, and Undisclosed Investors | Bird B, BOLD Capital Partners, Cota Capital, DCVC, HTC, Intel, and Undisclosed Investors | |||
Sources | 2 | 2 | 4 |
Cota Capital Portfolio Exits
25 Portfolio Exits
Cota Capital has 25 portfolio exits. Their latest portfolio exit was Miroculus on March 16, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
3/16/2023 | Acquired | 3 | |||
2/22/2023 | Acquired | 4 | |||
12/9/2022 | Reverse Merger | 8 | |||
Date | 3/16/2023 | 2/22/2023 | 12/9/2022 | ||
|---|---|---|---|---|---|
Exit | Acquired | Acquired | Reverse Merger | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 3 | 4 | 8 |
Cota Capital Fund History
8 Fund Histories
Cota Capital has 8 funds, including Cota Opportunities VI.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
3/20/2020 | Cota Opportunities VI | Diversified Private Equity | Closed | $3.5M | 1 |
12/30/2019 | Cota Opportunities V | ||||
4/22/2019 | Cota Opportunities IV | ||||
2/7/2019 | Cota Opportunities III | ||||
5/21/2018 | Cota Opportunities II |
Closing Date | 3/20/2020 | 12/30/2019 | 4/22/2019 | 2/7/2019 | 5/21/2018 |
|---|---|---|---|---|---|
Fund | Cota Opportunities VI | Cota Opportunities V | Cota Opportunities IV | Cota Opportunities III | Cota Opportunities II |
Fund Type | Diversified Private Equity | ||||
Status | Closed | ||||
Amount | $3.5M | ||||
Sources | 1 |
Cota Capital Service Providers
1 Service Provider
Cota Capital has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Counsel | General Counsel |
Service Provider | |
|---|---|
Associated Rounds | |
Provider Type | Counsel |
Service Type | General Counsel |
Partnership data by VentureSource
Cota Capital Team
6 Team Members
Cota Capital has 6 team members, including , .
Name | Work History | Title | Status |
|---|---|---|---|
Ullas Naik | Globespan Capital Partners, Icon Ventures, Broadpoint Capital, and FAC Equities | Founder | Current |
Name | Ullas Naik | ||||
|---|---|---|---|---|---|
Work History | Globespan Capital Partners, Icon Ventures, Broadpoint Capital, and FAC Equities | ||||
Title | Founder | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
